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In the June 2007 issue of Genome
Biology Gregory Petsko published [1] a
sweeping attack on both the objectives
and achievements of the Protein
Structure Initiative (PSI) [2]. As
members of the Forum for European
Structural Proteomics [3]) and SPINE2-
COMPLEXES (a European Commission
(EC) Integrated Project which is a
continuation of the Structural
Proteomics in Europe (SPINE)
consortium [4], the first structural
proteomics integrated project funded
by the EC), we wish to respond from a
European perspective.
It is not unusual for new and challen-
ging scientific endeavors to arouse the
criticism of parts of the scientific
community. As an example, few would
now wish to argue against the value of
the Human Genome Project, although
in its early days there were many
eminent contrarians. Although direct
benefits to drug companies may not
have been initially intended, they are a
positive outcome.
Petsko claims that the PSI has not
contributed to his own work, and makes
a bet that this is true for his readers. We
find this claim hard to swallow. Petsko
is, of course, entitled to speak for
himself, but we find it difficult to
believe that even he has not benefited
from the rapid advances in protein
production, crystallization and the
automation of both data collection and
structure determination that are direct
added value of the combined efforts
worldwide. Their utility to the
community can easily be assessed by
citations in the literature and visits to
websites. In particular, we would
dispute the assertion that there are no
longer problems in the process of
structure determination. For interest-
ing high-value targets, both protein
production and crystallization remain
significant challenges and require
further development. An example of the
hunger for such developments from the
broader structural biology community
is the remarkable interest in a publica-
tion from SPINE [4], cited recently by
the Faculty of 1000 as a ‘hidden’ gem.
Moreover, any structural biologist who
makes repeated visits to synchrotrons in
the United States, Europe and Japan is
each time amazed by the rapid and
ongoing advances in automation of data
collection and structure analysis, and in
the quality of the optics. Taken together,
they permit rapid data collection, with
remote access at some synchrotrons,
and use of crystals so small as to have
been unusable just a few years ago,
making it possible to attack previously
intractable problems. Nuclear magnetic
resonance methodology has been
similarly boosted by the PSI initiative,
resulting in dramatically increased
efficiency in structure determination, as
well as in fast, efficient and precise
approaches to a variety of biological
problems that would have been hard to
imagine even a few years ago. All these
achievements are an invaluable spin-off
of the PSI, and of its cousins outside the
United States, and would not have been
attained without the focused funding
and, perhaps more importantly, the
integrated and oriented teamwork
associated with these dedicated large-
scale centers.
As a result of the efforts of all consortia
(US, Japanese and European), 2,525
protein structures have been deposited
in the Protein Data Bank as of August
2007. Although some of these struc-
tures may be redundant (1,729 PSI
structures are unique by the 30%
sequence identity criterion) or even
appear uninteresting at first sight,
many are of the highest technical
quality, of fundamental and/or medical
importance and, taken overall, provide
a valuable database. Moreover, in
2005, structures arising out of
structural genomics and structural
proteomics efforts accounted for 44%
of the total number of novel structures
reported [6].
Until quite recently, most would have
agreed with Petsko’s comments on the
limited value of the large number of
new structures produced by the PSI for
use in homology modeling, and would
have questioned how valuable such
structures might really be for
accurately predicting novel protein
structures or for use in drug design.
But there are now an increasing
number of examples where predicted
structures have proved of utility,
including in drug design [7-9].
Obviously, the larger the database at
the disposal of the scientist, the better
will be the quality of the homology
models generated, whether of native
proteins, engineered proteins or of
drug-protein complexes. Thus,
although protein structures arising out
of structural genomics projects have
not yet led to a drug in clinical use, the
situation might well change quite
rapidly.
The fact that the only targeting
guidelines for the first round of the PSI
were to increase coverage of structure
space, permitted centers to focus on
sets of proteins from, for example, a
single organism. This was a reasonable
initial choice, as it permitted bench-
marking of a variety of parameters
highly relevant to the entire chain from
cloning to structure determination, and
highlighted the bottlenecks at the stages
of expression and crystallization, result-
ing in such insights as the Gravy plot
[10]. In its second round, the emphasis
of the PSI is still on increasing coverage
of structure space, but in a more
specific fashion, and with tight central
integration of target selection by the
various centers.
In the European Commission’s Vth
Framework Programme for Scientific
and Technological Cooperation, the
SPINE integrated project already
placed emphasis on identifying protein
targets related to human health and
disease, particularly on the solution of
human and pathogen protein structures
[11]. SPINE2-COMPLEXES, in the VIth
Framework Programme, has moved
from upgrading technologies and solving
structures of single proteins to develop-
ing approaches to solving the structures
of protein complexes, with the eventual
challenging objective of integrating
such complexes into higher-order
cellular structures. The measure of the
success of the project will not be the
number of structures solved but rather
their biological impact. The Structural
Genomics Consortium [12], an inter-
national project funded by Canada,
Sweden, the Wellcome Trust in the UK
and industry, with laboratories in
Oxford, Stockholm and Toronto, has
also focused on sets of proteins related
to human health. It is using structural
genomics methodology to develop high-
throughput approaches for attacking
these difficult targets with a high degree
of success [13].
In conclusion, it should be kept in mind
that scientific research, and the cutting-
edge technologies that both drive and
are driven by it, are constantly and
rapidly evolving. Some of Petsko’s
criticisms are constructive, and should
be noted by policy-makers. But one
should not throw the baby out with the
bathwater, rather tune the scope and
objectives of the PSI to the needs of the
life-science community as a whole,
much in the spirit of SPINE, the SGC
and other European structural genomics/
proteomics projects [14]. If such a
constructive approach is adopted, we
feel confident that the structural data
provided by the PSI and its cousins will
serve as no less valuable a resource than
genome sequences.
Gregory A Petsko responds:
The arguments of members of the
Forum for European Structural
Proteomics in response to my column
on the Protein Structure Initiative (PSI)
don't persuade me to change my view of
the usefulness of large-scale structural
genomics. Ultimately, the disagreement
is a philosophical one. Supporters of the
PSI - a group that, I still say, consists
largely of members of the PSI - believe
that the creation of a large database of
solved protein structures has great
value, at least potentially. I don't think
it does, and I made my reasons clear
enough in my column.
But a few of their comments are worth
responding to further. They "find it
difficult to believe that even he (that is,
me) has not benefited from the rapid
advances in protein production,
crystallization and the automation of
both data collection and structure
determination, that are direct added
value of the combined efforts
worldwide". Believe it, gang: it hasn't
done a thing for me. The 'benefits' the
correspondents set out are the
automation of both data collection and
structure determination - that is,
things that benefit primarily high-
throughput structure determination. I
don't do high-throughput structure
determination. It's against everything I
believe about the role of structure
determination in biology. The advances
they are talking about are primarily
advances that benefit themselves and
others involved in such projects.
The other comment I would respond to
is their suggestion that the larger
community should work with them to
recraft their mission so that it serves us
better. I suppose I ought to thank them
for making my point for me: after all
the time and money spent on this
program, they still are not sure
themselves what it is really good for.
I'm sorry, but I think that in this era of
tight funding for research, when there is
so much exciting, hypothesis-driven
science that needs to be done, there
simply is no room for a project that
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never had a compelling reason for
existence in the first place, and still
doesn't.
I don't think we should engage the
structural genomics groups in a dialog
over how to reformulate their goals
because I don't believe there is any goal
they can accomplish that is worth the
cost, in either money or human
resources. I still am convinced that the
kindest thing, and the only right thing,
we can do is to figure out how to phase
this program out with as little pain as
possible to those involved.
Gregory A Petsko
Correspondence: Rosenstiel Basic Medical Sci-
ences Research Center, Brandeis University,
Waltham, MA 02454-9110, USA. Email:
petsko@brandeis.edu
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